GT Biopharma, Inc. Email Format
Biotechnology ResearchCalifornia, United States2-10 Employees
Using our proprietary platform technology, GT Biopharma is generating novel immuno-oncology biopharmaceutical drugs targeting cancers such as acute myeloid leukemia, myeloid dysplastic syndrome, and multiple solid tumors by leveraging our proprietary NK cell engager (TriKE) platform technology. (NASDAQ: GTBP)